Innate Pharma (NASDAQ:IPHA) Stock Gets Downgrade from Leerink Partners

Innate Pharma (NASDAQ:IPHA – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Thursday, Marketbeat.com reports. They currently have a $1.00 target price on the stock. Leerink Partners‘s price target would suggest a potential upside of 15.82% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. BTIG Research restated a “buy” rating on shares of Innate Pharma in a research report on Thursday, November 5th. HC Wainwright restated a “buy” rating on shares of Innate Pharma in a research report on Monday, September 21st. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Innate Pharma in a report on Tuesday, September 22nd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.67.

Check Out Our Latest Analysis on Innate Pharma

Innate Pharma Stock Down 8.1%

Innate Pharma stock opened at $0.86 on Thursday. Innate Pharma has a 12-month low of $0.83 and a 12-month high of $2.71. The firm’s 50-day moving average is $1.53 and its two-hundred day moving average is $1.68.

Innate Pharma Company Profile

(Get Free Report)

Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.

See Also

Analyst Recommendations for Innate Pharma (NASDAQ:IPHA)

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.